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Abstract 
 
Thirteen common susceptibility loci have been reproducibly associated with cutaneous 
malignant melanoma (CMM). We report the results of an international two-stage meta-
analysis of 11 genome-wide association studies (GWAS, five unpublished) of CMM and 
Stage two datasets, totaling 15,990 cases and 26,409 controls. Five loci not previously 
associated with CMM risk reached genome-wide significance (P < 5×10-8) as did two 
previously-reported but un-replicated loci and all thirteen established loci. Novel SNPs fall 
within putative melanocyte regulatory elements, and bioinformatic and eQTL data highlight 
candidate genes including one involved in telomere biology. 
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Cutaneous malignant melanoma (CMM) primarily occurs in fair-skinned individuals; the 
major host risk factors for CMM include pigmentation phenotypes1-4, the number of 
melanocytic nevi5,6 and a family history of melanoma7. 
 
Six population-based genome-wide association studies (GWAS) of CMM have been 
published8-13 identifying 12 regions that reach genome-wide significance. Some of these 
regions were already established melanoma risk loci, for example through candidate gene 
studies14 (For review see15). A 13th region in 1q42.12, tagged by rs3219090 in PARP1, that 
was borderline in the initial publication (P = 9.3 × 10-8)13 was confirmed as genome-wide 
significant by a recent study (P = 1.03 × 10-8)16. As might be expected for common variants 
influencing CMM risk many of these loci contain genes that are implicated in one of the two 
well-established heritable risk phenotypes for melanoma, pigmentation (SLC45A2, TYR, 
MC1R and ASIP) and nevus count (CDKN2A/MTAP, PLA2G6 and TERT). The presence of 
DNA repair genes such as PARP1 and ATM at two loci suggests a role for DNA 
maintenance pathways, leaving four loci where the functional mechanism is less clear 
(ARNT/SETDB1, CASP8, FTO and MX2) (Supplementary Table S1). 
 
Of particular interest is TERT, which is involved in telomere maintenance; SNPs in this 
region have been associated with a variety of cancers9,17-21. Further, ATM and PARP1’s 
DNA repair functions extend to telomere maintenance and response to telomere 
damage22,23. Longer telomeres have been associated with higher nevus counts and it has 
been proposed that longer telomeres delay onset of cell senescence, allowing further time 
for mutations leading to malignancy to occur18,24. There is evidence that longer telomeres 
increase melanoma risk18,25,26 and that other telomere-related genes are likely involved in the 
etiology of melanoma, but none of these loci has yet reached genome-wide significance (or 
even P < 10-6)27. 
 
In addition, two independent SNPs at 11q13.3, near CCND1, and 15q13.1, adjacent to the 
pigmentation gene OCA2, have been associated previously with melanoma, but did not 
meet the strict requirements for genome-wide significance, either not reaching P = 5 × 10-8 in 
the initial report, or not replicating in additional studies8,9,28. This meta-analysis has resolved 
the status of these two loci, as well as identified novel melanoma susceptibility loci. 
 
Results and Discussion 
 
Law et al.,  
Page 6 of 32 
We conducted a two-stage genome-wide meta-analysis. Stage one consisted of 11 GWAS 
totaling 12,874 cases and 23,203 controls from Europe, Australia and the USA; including all 
six published CMM GWAS and five unpublished ones (Supplementary Table S2). In Stage 
two we genotyped 3,116 CMM cases and 3,206 controls from three additional datasets 
(consisting of 1,692 cases and 1,592 controls from Cambridge, UK, 639 cases and 823 
controls from Breakthrough Generations, UK, and 785 cases and 791 controls from Athens, 
Greece; Online Methods) for the most significant SNP from each region reaching P < 10-6 
and included these results in an Overall meta-analysis of both stages, totaling 15,990 
melanoma cases and 26,409 controls. Details of these studies can be found in 
Supplementary Material. Given that the previous single-largest melanoma GWAS was of 
2,804 cases and 7,618 controls9, this meta-analysis represents a fourfold increase in sample 
size compared to previous efforts to identify the genetic determinants of melanoma risk. 
Unless otherwise indicated we report the P-values from Overall meta-analysis combining the 
two stages (Supplementary Table S3). 
 
All Stage one studies underwent similar quality control (QC) procedures, were imputed using 
the same reference panel and the results analyzed in the same way, with the exception of 
the Harvard and MDACC studies (see Online Methods). Fixed effects (Pfixed) or random 
effects (Prandom) meta-analysis was conducted as appropriate depending on between-study 
heterogeneity. 9,470,333 imputed variants passed QC in at least two studies, of which 3,253 
reached Pfixed < 1 × 10
-6 and 2,543 reached Pfixed < 5 × 10
-8. For reference we provide a list of 
SNPs that reached a Pfixed, or Prandom if I
2 > 31%, value < 1 × 10-7 (Supplementary Table S4). 
The Stage one meta-analysis genome-wide inflation value (λ) was 1.032, and as λ increases 
with sample size we also adjusted the λ to a population of 1000 cases and 1000 controls29. 
The resulting λ1000 of 1.002 suggested minimal inflation. Quantile-quantile (QQ) plots for the 
Stage one meta-analysis and individual GWAS studies can be found in Supplementary 
Figures S2 and S3. To further confirm that our results were not influenced by inflation, the 
Stage one meta-analysis was repeated correcting for individual studies’ λ; P-values were 
essentially unchanged (Online Methods, Supplementary Table S3). 
 
All 13 previous reported genome-wide significant loci (most first identified in one of the 
studies included here) reached P < 5 × 10-8 in Stage one (Figure 1, Supplementary Table 
S4). In addition to confirming the two previously-reported sub-genome-wide significant loci at 
11q13.3 (rs498136, 89 kb from CCND1) and 15q13.1 (rs4778138 in OCA2) we found three 
novel loci reaching genome-wide significance at 6p22.3, 7p21.1, and 9q31.2 (Table 1; 
Figure 2). Forest plots of the individual GWAS study results can be found in Supplementary 
Figure S1. SNPs in another 16 regions reached P < 10-6 (Supplementary Table S3), notably, 
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three were close to known telomere-related genes (rs2995264 is in OBFC130 in 10q24.33, 
rs11779437 is 1.1 Mb from TERF131 in 8q13.3, and rs4731207 is 66 kb from POT1 in 
7q31.33, in which loss-of-function variants occur in some melanoma families32,33). Given the 
importance of telomeres in melanoma we additionally genotyped two SNPs that did not quite 
reach our P < 10-6 threshold but are close to telomere-related genes34: rs12696304 in 3q26.2 
(Pfixed = 1.6 × 10
-5) is 1.1 kb from TERC and rs75691080 in 20q13.33 (Pfixed = 1.0 × 10
-6) is 
19.4 kb from RTEL1. 
 
Including the Stage two results in the Overall meta-analysis led to two new genome-wide 
significant regions, 2p22.2 and 10q24.33 (Figure 2; Table 1, Supplementary Table S3). The 
Stage two data also serve the purpose of independently confirming with genotype data the 
meta-analysis results from imputed SNPs. Five SNPs, rs4778138 (OCA2/15q13.1), 
rs498136 (CCND1/11q13.3), and the novel rs10739221 (9q31.2), rs6750047 (2p22.2) and 
rs2995264 (10q24.33) all reached P < 0.05 in the genotyped replication samples. We have 
estimated the power to reach P < 0.05 in the Stage two samples for all SNPs that reached 
genome-wide significance in the Stage one meta-analysis (Online Methods, Supplementary 
Table S5). rs6914598 (6p22.3) was only genotyped in the Athens sample and thus had a 
power of only 0.35. Of the remaining four SNP that were genome-wide significant in Stage 
one, while the 7p21.1 SNP rs1636744 was well powered (>90%), the probability that all four 
of these well-powered SNPs would replicate was only (0.916 × 0.736 × 0.787 × 0.955) = 
0.51, so it is not surprising that one failed to replicate. While SNPs in 7p21.1 (rs1636744) 
and 6p22.3 (rs6914598) did not reach nominal significance in Stage two, for both SNPs the 
confidence intervals for the effect estimates overlapped the Stage one meta-analysis. 
 
In terms of heritability the 13 loci that were genome-wide significant before this meta-
analysis explained 16.9% of the familial relative risk (FRR) for CMM, with MC1R explaining 
5.3% alone (Online Methods). Including the seven loci confirmed or reported here (2p22.2, 
6p22.3, 7p21.1, 9q31.2, 10q24.33, 11q13.3, 15q13.1), an additional 2.3% of FRR is 
explained. In total, all 20 loci explain 19.2% of the FRR for CMM; this is a conservative 
estimate given the assumption of a single SNP per locus. 
 
We tested all new and known CMM risk loci for association with nevus count or pigmentation 
(Supplementary Table S1). Aside from the known association between OCA2 and 
pigmentation, none of the newly-identified loci were associated (P > 0.05). Following 
confirmation of the loci in Stage two we performed conditional analysis on the Stage one 
meta-analysis results to determine whether there were additional association signals within 1 
Mb either side of the top SNP using the Genome-wide Complex Trait Analysis (GCTA) 
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software35 (http://www.complextraitgenomics.com/software/gcta/; Online Methods; 
Supplementary Table S6). This indicated that while there are additional SNPs associated 
with CMM at each locus, for all but chromosome 7 and 11 the additional signals were not 
strongly associated with melanoma (P < 1 × 10-7). We then conducted a comprehensive 
bioinformatic assessment of the top SNP from each of the seven new genome-wide 
significant loci using a range of annotation tools, databases of functional and eQTL results 
and previously-published GWAS results (see Online Methods, Supplementary Table S7). 
We applied the same analyses to each locus but, to limit repetition, where nothing was found 
for a given resource (e.g. NHGRI GWAS catalog) we do not explicitly report this. 
 
2p22.2 
 
While rs6750047 in 2p22.2 was not genome-wide significant in the Stage one meta-analysis 
it was associated with at genome-wide significance (Pfixed = 7.0 × 10
-9, OR = 1.10, I2 = 0.00; 
Table 1, Supplementary Table S3) in the Stage two and Overall meta-analysis. The 
association signals for 2p22.2 (Figure 2) span the 3' UTR of RMDN2 (also known as 
FAM82A1) and the entirety of the CYP1B1 gene, and as such there is a wealth of 
bioinformatic annotation for SNPs associated with CMM risk. Considering the 26 SNPs with 
P-values within two orders of magnitude of rs6750047 in 2p22.2 (Supplementary Table S7), 
HaploReg (http://www.broadinstitute.org/mammals/haploreg/)36 reports a significant 
enrichment of strong enhancers in epidermal keratinocytes (4 observed, 0.6 expected, P = 
0.003). The paired rs162329 and rs162330 (LD r2 =1.0, 98bp apart; Pfixed = 3.91 ×10
-6, I2 = 
11.23) lie approximately 10 kb upstream from the CYP1B1 transcription start site in a 
potential enhancer in keratinocytes and other cell types36-39. These two SNPs are eQTLs for 
CYP1B1 in three independent liver sample sets40,41. In addition several SNPs, including the 
peak SNP for 2p22.2, rs6750047, are strong CYP1B1 eQTLs in LCLs in the Multiple Tissue 
Human Expression Resource42 (MuTHER; P < 5 × 10-5). It is worth noting the overlap 
between the liver and lymphoblastoid cell line (LCL) eQTLs is incomplete; rs162330 and 
rs162331 are only weak eQTLs in MuTHER data (P ~ 0.01). In terms of functional 
annotation the most promising SNP near rs6750047 is rs1374191 (Pfixed = 5.4 × 10
-5, OR = 
1.07, I2 = 0.00); in addition to being a CYP1B1 eQTL in LCLs (MuTHER P = 6.9 × 10-8), this 
SNP is positioned in a strong enhancer region in multiple cell types including melanocytes 
and keratinocytes36-39. In summary, SNPs in 2p22.2 associated with melanoma lie in putative 
melanocyte and keratinocyte enhancers and are also cross-tissue eQTLs for CYP1B1. 
 
CYP1B1 metabolizes endogenous hormones, playing a role in hormone associated cancers 
including breast and prostate (reviewed in43). CYP1B1 also metabolizes exogenous 
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chemicals, resulting in pro-cancer (e.g. polycyclic aromatic hydrocarbons) and anti-cancer 
(e.g. tamoxifen) outcomes43. The former is of interest as CYP1B1 is regulated by ARNT, a 
gene at the melanoma-associated 1q21 locus13. The CYP1B1 promotor is methylated in 
melanoma cell lines and tumor samples44. CYP1B1 missense protein variants have been 
associated with cancers including squamous cell carcinoma and hormone associated 
cancers43,45. Of these only rs1800440 (N453S) is moderately associated with melanoma 
(Pfixed = 1.83 × 10
-5, OR = 0.90, I2 = 0.00), and it was included in the bioinformatic annotation 
(Supplementary Table S7). rs1800440 is not in LD with the CMM risk meta-analysis peak 
SNP rs6750047/2p22.2 (LD r2=0.04) and adjusting for rs6750047 only slightly reduces its 
association with CMM (P = 4.3 × 10-4, Online Methods). Truncating mutations in CYP1B1 
are implicated in primary congenital glaucoma46 and as glaucoma cases are used as 
controls in the contributing WAMHS melanoma GWAS, we considered the impact of 
excluding glaucoma cases; the SNP remains genome-wide significantly associated with 
CMM after such exclusions (Supplementary Methods, Supplementary Table S8). While the 
association with melanoma in the WAMHS set is stronger without glaucoma cases (beta 
0.05 vs. 0.19) both betas are within the range observed for other melanoma datasets and no 
heterogeneity (I2=0.00) is observed with or without the glaucoma samples. 
 
6p22.3 
 
rs6914598 (Pfixed = 3.5 × 10
-8, OR = 1.11, I2 = 0.00) lies in 6p22.3, in intron 12 of CDKAL1, a 
gene that modulates the expression of a range of genes including proinsulin via tRNA 
methylthiolation47,48. Bioinformatic assessment of the 35 SNPs with P-values within two 
orders of magnitude of the 6p22.3 peak rs6914598 by HaploReg36 indicates the most 
functionally interesting SNP is rs7776158 (Stage one Pfixed = 3.8 × 10
-8, I2 = 0, in complete 
LD with rs6914598, r2=1.0), which lies in a predicted melanocyte enhancer that binds 
IRF437,38. IRF4 binding is of interest given the existence of a functional SNP rs12203592 in 
the IRF4 gene49, associated with nevus count, skin pigmentation and tanning response50-53. 
 
7p21.1 
 
rs1636744 (Pfixed = 7.1 × 10
-9, OR = 1.10, I2 = 0.00; Figure 2) is in an intergenic region of 
7p21.1 and lies 63 kb from AGR3. rs1636744 is an eQTL for AGR3 in lung tissue (GTEx P = 
1.6 × 10-6)54. AGR3 is a member of the protein disulphide isomerase family which generate 
and modify disulphide bonds during protein folding55. AGR3 expression has been associated 
with breast cancer risk56 and poor survival in ovarian cancer57. GTEx confirms that AGR3 is 
expressed in human skin samples. Evidence that the regions containing rs1636744 are not 
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conserved in primates (UCSC genome browser58), and RegulomeDB 
(http://RegulomeDB.org/)39 indicates there is little functional activity at this SNP. More 
promising are rs847377 and rs847404 which, in addition to being both AGR3 eQTLs in lung 
tissue54 and associated with CMM risk (Stage one Pfixed = 3.89 × 10
-8 and 1.72 × 10-7), are in 
putative weak enhancers in a range of cells including melanocytes and keratinocytes36-39. 
Adjusting for rs1636744 renders rs847377 and rs847404 non-significant (P > 0.6) indicating 
that they are tagging a common signal. rs1636744, rs847377 and rs847404 are not eQTLs 
for AGR3 in sun-exposed skin. 
 
9q31.2 
 
The melanoma-associated variants at 9q31.2, peaking at rs10739221 (Overall Pfixed = 7.1 × 
10-11; I2 = 0.00; Figure 2) are intergenic. The nearest genes are TMEM38B, ZNF462 and the 
nucleotide excision repair gene RAD23B59. While bioinformatic annotation did not reveal any 
putative functional SNPs, based on the importance of DNA repair in melanoma RAD23B is 
of particular interest. rs10739221 is 635 Kb from the leukemia-associated TAL260, and 1.2 
Mb from KLF4, which regulates both telomerase activity61 and the melanoma-associated 
TERT62. 
 
10q24.33 
 
While not genome-wide significant in Stage one, rs2995264 in 10q24.33 is strongly 
associated with telomere length27,34 and was genotyped in Stage two. The association of 
rs2995264 with CMM was significant in the Cambridge study (P = 0.046) and strong in the 
Breakthrough dataset (P = 8.0 × 10-4); in the Overall meta-analysis this SNP reached 
genome-wide significance (Pfixed = 2.2 × 10
-9; I2 = 27.14). The melanoma association signal 
at 10q24.33 (Figure 2) spans the OBFC1 gene and the promotor of SH3PXD2A. Given the 
strong telomere length association at this locus the most promising candidate is OBFC1, a 
component of the telomere maintenance complex30. 
 
HaploReg reports that SNPs within two orders of magnitude of rs2995264 in 10q24.33 are 
significantly more likely to fall in putative enhancers in keratinocytes than would be expected 
by chance. Promising candidate functional SNPs include the conserved rs11594668 and 
rs11191827 which lie in putative melanocyte and keratinocyte enhancers, and bind 
transcription factors36-39. The association observed at rs2995264/10q24.33 is independent of 
a recent report of a melanoma association at 10q25.163. Our peak SNP for 10q24.33, 
rs2995264, and the 10q25.1 SNPs rs17119434, rs17119461, rs17119490 reported in 
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Teerlink et al., (2012) are in linkage equilibrium (LD r2 <0.01) and in turn these SNPs are not 
associated with CMM in our meta-analysis (P > 0.2). 
 
11q13.3 
 
The CMM-associated variants at 11q13.3 peak at rs498136 (Overall Pfixed = 1.5 × 10
-12, OR = 
1.13, I2 = 0.00; Supplementary Figure S4) 5’ to the promotor of CCND1. In the initial report 
of CCND19 rs11263498 was borderline in its association with melanoma (P = 3.2 × 10-7) and 
while supported (P = 0.017) by the two replication studies exhibited significant heterogeneity 
and did not reach genome-wide significance (overall Prandom = 4.6 × 10
-4, I2 = 45.00). The 
previously-reported rs11263498 and the meta-analysis peak of rs498136/11q13.3 are in 
strong linkage disequilibrium (LD) (r2=0.95). 
 
Bioinformatic assessment of the CCND1 region indicated the peak SNP rs498136/11q13.3 
is in a putative enhancer in keratinocytes in both ENCODE and Roadmap data36-39. 
Considering other SNPs strongly associated with CMM, both the previously-reported9 
rs11263498 (Stage one Pfixed = 1.8 × 10
-9, OR = 1.12, I2 = 0.00) and rs868089 (Stage one 
Pfixed = 2.0 × 10
-9, OR = 1.12, I2 = 0.00) lie in putative melanocyte enhancers. 
 
Somatic CCND1 amplification in CMM tumors positively correlates with markers of reduced 
overall survival, including Breslow thickness and ulceration64,65. The CCND1 association with 
breast cancer has been extensively fine-mapped, revealing three independent association 
signals66. rs554219 and rs75915166 tag the two strongest functional associations with 
breast cancer66 but are not themselves associated with CMM risk (Stage one Pfixed > 0.1, I
2 = 
0.00). While the third signal in breast cancer was not functionally characterized66, its tag 
SNP rs494406 is modestly associated with CMM (Stage one Pfixed > 0.0002, I
2 = 0.00, LD 
r2=0.47 with rs498136/11q13.3). rs494406 is no longer significant after adjustment by 
rs498136 (P = 0.53; Supplementary Table S6), suggesting that SNPs that are in LD in this 
region are associated with both risk of melanoma and breast cancer. 
 
15q13.1 
 
Both OCA2 and nearby HERC2 in the 15q13.1 locus have long been associated with 
pigmentation traits50. rs12913832 in HERC2, also known as rs11855019, is the major 
determinant of eye color in Europeans67, making this region a strong candidate for CMM 
risk. One of the studies contributing to this meta-analysis previously reported a genome-wide 
significant association between melanoma and rs1129038 and rs12913832 in HERC2 (in 
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strong LD8 reported as r2 = 0.985), but this was not supported (P > 0.05) by any of the three 
replication GWAS (final P = 2.5 × 10-4)8. Stratification might be an issue for this locus as eye 
color frequencies vary markedly across European populations. Indeed, in our meta-analysis, 
which includes all four of these GWAS, both rs1129038 and rs12913832 showed highly 
heterogeneous effects in the CMM risk meta-analysis (Prandom = 0.037 and 0.075 
respectively, I2 > 77.00). 
 
Amos et al., (2011) found that rs4778138 in OCA2, which is only in weak LD with 
rs12913832 (r2 = 0.12), exhibited a more consistent association across studies, albeit not 
genome-wide significantly. In our Overall meta-analysis we confirm rs4778138 in 15q13.1 is 
associated with CMM risk (Pfixed
 = 2.2 × 10-11, OR = 0.84, I2 = 0.00; Figure 2). Following 
adjustment the 15q13.1 signal by rs4778138 the effect size for the eye color SNP 
rs12913832 is reduced from beta = 0.12 to beta = 0.064. Conversely adjustment for 
rs12913832 reduces rs4778138’s association with CMM (beta reduced from -0.178 to -
0.114, corrected P = 1.6 × 10-4). rs12913832 is poorly imputed across studies, reaching 
INFO > 0.8 in only 6 studies, and we are unable to conclusively exclude a role for 
rs12913832 at this locus. HaploReg indicates rs4778138 is within a putative melanocyte 
enhancer in Roadmap epigenetic data36-39. While it is not clear which gene(s) in 15q13.1 
is/are influenced by melanoma-associated SNPs, the fact that rs4778138 is associated with 
eye colors intermediate to blue and brown68 supports a role for OCA2. 
 
Evidence of additional melanoma susceptibility loci 
 
A further nine loci were associated with CMM risk at multiple SNPs with P < 10-6 in Stage 
one but did not reach P < 5 ×10-8 in the Overall meta-analysis (Supplementary Table S3). 
Given that genome-wide significance is based on a Bonferroni correction assuming 
1,000,000 independent tests, we would expect only one locus to reach P < 10-6 and the 
probability that as many as nine loci reach this threshold is 1.1 × 10-6 (exact binomial 
probability), so it is highly likely that several of these are genuine.  
 
Of the 16 regions that reached P < 10-6, three were near genes involved in telomere biology 
7q31.33 (rs4731207 near POT1), 8q13.3 (rs11779437 near TERF1), and 10q24.33 
(rs2995264 near OBFC1) (Supplementary Table S3). Given the evidence for telomere 
biology in melanoma18,24-27 and that previous genome-wide significant SNPs are near the 
telomere maintenance genes TERT, PARP1 and ATM, we included two further biological 
candidates: rs12696304, 1.1 kb from TERC in 3q26.2, and rs75691080 in 20q13.33 near 
RTEL1. Of these five SNPs, rs2995264 (10q24.33/OBFC1) attained genome-wide 
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significance in the overall analysis while rs12696304 (3q26.2/TERC) was significant in Stage 
two (P = 4.0 × 10-3), and reached P = 2.8 × 10-7 in the Overall meta-analysis (Supplementary 
Table S3). While falling short of genome-wide significance this is nonetheless suggestive of 
an association at this locus. Neither rs4731207 (66 kb from POT1 in 7q31.33) nor 
rs75691080 (19.4 kb from RTEL1 in 20q13.33) were significantly associated with melanoma 
risk in Stage two, but in neither case did the estimated effect differ significantly from Stage 
one. In addition rs75691080 (RTEL1/20q13.33) is marginally associated with nevus count (P 
= 0.058; Supplementary Table S1). Of the SNPs near telomere-related genes, rs11779437 
in 8q13.3 was the most distant (1.1 Mb from TERF1) and was the only one to show a 
significantly different effect in Stage two (Overall Prandom = 0.013, OR = 0.93, I
2 = 42.06). This 
is most likely due to the initial signal being a false positive, but may also be due to lack of 
power. 
 
Conclusion 
 
This two-stage meta-analysis, representing a fourfold increase in sample size compared to 
the previous largest single melanoma GWAS, has confirmed all thirteen previously reported 
loci, as well as resolving two likely associations at CCND1 and HERC2/OCA2. The CCND1 
association with melanoma only partially overlaps the signal observed for breast cancer66. 
The HERC2/OCA2 association is with rs4778138/15q13.1, which may be a subtle modifier 
of eye color68, but we cannot rule out that the association at this locus is influenced by the 
canonical blue/brown eye color variant rs12913832. 
 
Our Stage one meta-analysis of over 12,000 melanoma cases identified three novel risk 
regions, with only rs10739221 formally replicating (P < 0.05) in Stage two (Table 1). Two 
further loci (2p22.2 and 10q24.33) reached genome-wide significance with the addition of 
the Stage two data (Figure 2; Table 1, Supplementary Table S3). In total our Overall meta-
analysis identified 20 genome-wide significant loci; 13 previously replicated, two reported but 
confirmed here and five that are novel to this report. The new loci identified in this meta-
analysis explain an additional 2.3% of the familial relative risk for CMM. Overall, 19.2% of 
the FRR is explained by all 20 genome-wide significant loci combined. 
 
Except for the association at 9q31.2, reported loci contain SNPs that are both strongly 
associated with melanoma and fall within putative regulatory elements in keratinocyte or 
melanocyte cells with the nearby nucleotide excision repair gene RAD23B at 9q31.2 a 
promising candidate. eQTL datasets suggest that melanoma-associated SNPs at 7p21 
regulate the expression of AGR3 albeit in lung tissue and not sun-exposed skin. AGR3 
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expression has been implicated in breast and ovarian cancer outcome. SNPs in 2p22.3 are 
associated with the expression of CYP1B1. Although this gene is better known for its role in 
hormone-associated cancers it may influence melanoma risk through metabolism of 
exogenous compounds, a process regulated by ARNT at the 1q21 melanoma-associated 
locus. 
 
We have used the power of this large collection of CMM cases and controls to identify five 
novel loci, none of which are significantly associated with classical CMM risk factors and 
thus highlight novel disease pathways. Interestingly, we now have genome-wide significant 
evidence for association between CMM risk and a SNP in the telomere-related gene OBFC1 
in 10q24.33, in addition to the established associations at the TERT/CLPTM1L, PARP1 and 
ATM loci. We also have support, albeit not genome-wide significant, for TERC, the most 
significant predictor of leukocyte telomere length in a recent study34. Of the 20 loci that now 
reach genome-wide significance for CMM risk five are in regions known to be related to 
pigmentation, three in nevus-related regions and four in regions related to telomere 
maintenance. This gives further evidence that the telomere pathway, with its effect on the 
growth and senescence of cells, may be important in understanding the development of 
melanoma. 
 
URLs 
 
GenoMEL, http://www.genomel.org/ ; Wellcome Trust Case Control Consortium 
http://www.wtccc.org.uk/ ; RegulomeDB, http://RegulomeDB.org/; HaploReg 
http://www.broadinstitute.org/mammals/haploreg/; GTEx http://www.gtexportal.org, MuTHER 
http://www.muther.ac.uk/, eQTL data accessed via GeneVAR 
http://www.sanger.ac.uk/resources/software/genevar/, eQTL Browser 
http://eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl/ ; NHGRI GWAS catalog: 
http://www.genome.gov/gwastudies/; Genome-wide Complex Trait Analysis (GCTA) 
http://www.complextraitgenomics.com/software/gcta/; GTOOL 
http://www.well.ox.ac.uk/~cfreeman/software/gwas/gtool.html; Cancer Oncological Gene-
environment Study (http://www.nature.com/icogs/primer/common-variation-and-heritability-
estimates-for-breast-ovarian-and-prostate-cancers/#70) 
 
Online Methods 
 
Stage one array genotyping 
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The samples were genotyped on a variety of commercial arrays, detailed in the 
Supplementary Methods. 
 
Stage one genome-wide imputation 
 
Imputation was conducted genome-wide, separately on each study, following a shared 
protocol. SNPs with MAF < 0.03 (MAF < 0.01 in AMFS, Q-MEGA_omni, Q-MEGA_610k, 
WAMHS, and HEIDELBERG), control HWE P < 10-4 or missingness > 0.03 were excluded, 
as were any individuals with call rates <0.97, identified as first degree relatives and/or 
European outliers by principal components analysis using Eigenstrat69. In addition, in each 
study where genotyping was conducted on more than one chip, any SNP not present on all 
chips was removed prior to imputation to avoid bias. IMPUTEv2.270,71 was used for 
imputation for all studies but Harvard, which used MaCH72,73 and MDACC which used MaCH 
and minimac74 . For GenoMEL, CIDRUK and MDACC samples the 1000 Genomes Feb 
2012 data (build 37) was used as the reference panel, while for the AMFS, Q-MEGA_omni, 
Q-MEGA_610k, WAMHS, MELARISK and HEIDELBERG datasets the 1000 Genomes April 
2012 data (build 37) was the reference for imputation75. In both cases any SNP with MAF < 
0.001 in European (CEU) samples was dropped from the reference panel. The HARVARD 
data were imputed using MACH with the NCBI build 35 of phase II HapMap CEU data as the 
reference panel and only SNPs with imputation quality R2 > 0.95 were included in the final 
analysis. 
 
Stage one genome-wide association analysis 
 
Imputed genotypes were analyzed as expected genotype counts based on posterior 
probabilities (gene dosage) using SNPTEST276 assuming an additive model with geographic 
region as a covariate (SNPTEST v2.5 for chromosome X). MDACC imputed genotypes were 
analyzed using best guess genotypes from MACH and PLINK was used for logistic 
association test adjusting by the top two principle components. Only those with an 
imputation quality score (INFO/MaCH r2) score >0.8 were analyzed. Potential stratification 
was dealt with in the GenoMEL samples by including geographic region as a covariate 
(inclusion of principal components as covariates was previously found to make little 
difference10) and elsewhere by including principal components as covariates69. 
 
Meta-analysis 
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Heterogeneity of per-SNP effect sizes in studies contributing to the Stage one, Stage two 
and the Overall meta-analyses was assessed using the I2 metric77. I2 is commonly defined as 
the proportion of overall variance attributable to between-study variance, with values below 
31% suggesting no more than mild heterogeneity. Where I2 was less than 31% a fixed 
effects model was used, with fixed effects P-values indicated by Pfixed; otherwise random 
effects were applied (Prandom). The method of Dersimonian and Laird
78 was used to estimate 
the between-studies variance, ?̂?2. An overall random effects estimate was then calculated 
using the weights 1 (𝜈𝑖 + ?̂?
2)⁄  where 𝜈𝑖 is the variance of the estimated effect. ?̂?
2=0 for the 
fixed effects analyses. We report those loci reaching significance at > one marker 
incorporating information from > one study. Results for rs186133190 in 2p15 were only 
available from four studies; all other SNPs reported here utilize data from at least eight 
studies (Supplementary Table S3). 
 
Per-study QQ plots of GWAS P-values are provided (Supplementary Figure S3) and for the 
Stage one meta-analysis (Supplementary Figure 3A). We also provide the Stage one QQ 
plot with previously reported regions removed (Supplementary Figure S2B). While there was 
minimal inflation remaining following PC/region of origin correction, to ensure residual 
genomic inflation was not biasing our results the meta-analysis was repeated using the 
genome-wide association meta-analysis software, GWAMA v2.179. Included studies were 
corrected by inflating SNP variance estimates by their genomic inflation (λ). As expected, 
given the low level of residual inflation, corrected and uncorrected results were very similar; 
GIF-corrected P-values are provided in Supplementary Table S3. 
 
Where pairwise linkage disequilibrium measures are given, these were estimated from 1000 
Genomes Phase 1 March 2012 European (CEU and GBR) using PLINK80 or the --hap-r2 
command in vcftools unless otherwise indicated. 
 
Stage two genotyping 
 
A single SNP for each novel region reaching P < 10-6 in Stage one was subsequently 
genotyped in 3 additional melanoma case-control sets (Supplementary Table S3). Any 
regions that only showed evidence for association with CMM at a single imputed SNP and in 
only one study were not followed up. Included in the Stage two genotyping were rs75691080 
in 20q13.33 which, while not quite reaching P < 10-6 lies 20 kb from RTEL1; and rs12696304 
in 3q26.2 which lies 1 kb from TERC. Both these genes are known to be telomere-related 
and have been associated with leukocyte telomere length34. Also genotyped was rs2290419 
Law et al.,  
Page 17 of 32 
at 11q13.3 which is 450 kb away from our primary hit in the region of CCND1 (rs498136, 
Supplementary Figure S4) and is in linkage equilibrium with the genome-wide significant hit 
in this region (r2 = 0.002) so may represent an independent effect.  
 
The first Stage two dataset of 1,797 cases and 1,709 controls from two studies based in 
Cambridge, UK (see Supplementary Material for details of samples). These were genotyped 
using TaqMan® assays (Applied Biosystems). 2 μl PCR reactions were performed in 384 
well plates using 10 ng of DNA (dried), using 0.05 μl assay mix and 1 μl Universal Master 
Mix (Applied Biosystems) according to the manufacturer’s instructions. End point reading of 
the genotypes was performed using an ABI 7900HT Real-time PCR system (Applied 
Biosystems). 
 
The second was 711 cases and 890 controls from the Breakthrough Generations Study. 
These were genotyped in the same way as the Cambridge replication samples above. 
 
The third was 800 cases and 800 controls from Athens, Greece. Genomic DNA was isolated 
from 200μl peripheral blood using the QIAamp DNA blood mini kit (Qiagen). DNA 
concentration was quantified in samples prior to genotyping by using Quant-iT dsDNA HS 
Assay kit (Invitrogen). The concentration of the DNA was adjusted to 5 ng/μl. Selected SNPs 
were genotyped using the Sequenom iPLEX assay (Sequenom, Hamburg, Germany). Allele 
detection in this assay was performed using matrix-assisted laser desorption/ionization –
time-of-flight mass spectrometry81. Since genotyping was performed by Sequenom, specific 
reaction details are not available. As it is described by Gabriel et al, the assay consists of an 
initial locus-specific PCR reaction, followed by single base extension using mass-modified 
dideoxynucleotide terminators of an oligonucleotide primer which anneals immediately 
upstream of the polymorphic site of interest. Using MALDI-TOF mass spectrometry, the 
distinct mass of the extended primer identifies the SNP allele.  
 
Genotyping of 18 SNPs was attempted in Stage two; the rs186133190/2p15. 
rs6750047/2p22.2, rs498136/11q13.3 and rs4731742/7q32.3 assays failed in one or more 
Stage two datasets (Supplementary Table S3). After QC (excluding individuals missing >1 
genotype call, SNPs missing in >3% of samples, SNPs with HWE P < 5 × 10-4) there were 
1,692 cases and 1,592 controls from Cambridge, 639 cases and 823 controls from 
Breakthrough Generations and 785 cases and 791 controls from Athens, Greece available 
for analysis.  
 
Statistical power for Stage two 
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We have estimated the power to reach P < 0.05 in the Stage two samples for all SNPs that 
reached genome-wide significance in the Stage one meta-analysis (Supplementary Table 
S3). We converted ORs to genotype relative risks (as the SNPs are relatively frequent this is 
a reasonable assumption) and estimated power by simulating cases and controls (10,000 
iterations) and conducting a Cochran-Armitage trend test (see Supplementary Table S5). 
 
Conditional Analysis 
 
Genome-wide Complex Trait Analysis (GCTA 
http://www.complextraitgenomics.com/software/gcta/ 35) was used to perform 
conditional/joint GWAS analysis of newly identified or confirmed loci. GCTA allows 
conditional analysis of summary meta-analysis if provided with a sufficient large reference 
population (2-5,000 samples) to estimate LD. We used the QMEGA-610k set as a reference 
population to determine LD. QMEGA-610k imputation data for well imputed SNPs (INFO > 
0.8) was converted to best guess genotypes using the GTOOL software 
(http://www.well.ox.ac.uk/~cfreeman/software/gwas/gtool.html). 
 
Following best-guess conversion (genotype probability threshold 0.5), SNPs with MAF <0.01 
and > 3% missingness were removed. As per Yang et al., (2011) we further cleaned the 
QMEGA-610K dataset to include only completely unrelated individuals (Identity by descent 
score ≤ 0.025 versus the standard 0.2 used in the meta-analysis), leaving a total of 4,437 
people and 7.24 million autosomal SNPs in the reference panel. 
 
Stage one fixed effects summary meta-analysis data for SNPs within 1 Mb either side of the 
top SNP within each new locus were adjusted for the top SNP using the --cojo-cond option. 
As per Yang et al., (2011) we used the genomic control corrected GWAS-meta-analysis 
results. If there was an additional SNP with P < 5 × 10-8 following adjustment for the top SNP 
we performed an additional round including both SNPs. If the remaining SNPs had P-values 
greater than 5 × 10-8 no further analysis was performed. The results of this analysis are 
reported in Supplementary Table S6. 
 
Proportion of Familial Relative Risk 
 
We have used the formula for calculating the proportion of familial relative risk (FRR) as 
outlined by the Cancer Oncological Gene-environment Study 
(http://www.nature.com/icogs/primer/common-variation-and-heritability-estimates-for-breast-
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ovarian-and-prostate-cancers/#70). Given that CMM incidence is low, and the odds ratios 
reported small, we have assumed the odds ratios derived from the Stage one meta-analysis 
are equivalent to relative risks. With this assumption we have estimated the proportion of the 
FRR explained by each SNP (FRRsnp) as FRRsnp = (pr
2 + q)/ (pr + q)2 
 
Where risk allele and alternative allele frequency are p and q respectively, and r is the odds 
ratio for the risk allele  
 
Assuming a FRRmelanoma for CMM of 2.19
82 and using the combined effect of all SNPs 
(assuming a multiplicative effect and a single SNP per loci), we computed the proportion of 
FRR is explained by a set of SNPs as Natural_log(product of 
FRRsnp)/Natural_log(FRRmelanoma). 
  
 
Association with nevus count or pigmentation 
 
Pigmentation and nevus phenotype data were available for 980 melanoma cases and 499 
control individuals from the Leeds case-control study83,84. Additional individuals from the 
Leeds melanoma cohort study85 included pigmentation data giving a total of 1,458 subjects 
with melanoma and 499 control subjects. For the most significant SNP in each region 
reaching P < 1 × 10-6 in the initial meta-analysis, logged age- and sex-adjusted total nevus 
count was regressed on the number of risk alleles, adjusting for case-control status. A sun-
sensitivity score was calculated for all subjects based on a factor analysis of six 
pigmentation variables (hair color, eye color, self-reported freckling as a child, propensity to 
burn, ability to tan and skin color on the inside upper arm)19. This score was similarly 
regressed on number of risk alleles and adjusted for case-control status. Full results can be 
found in Supplementary Table S1. 
 
Bioinformatic annotation 
 
As the SNP most associated with the phenotype is quite likely not the underlying functional 
variant86 at each locus we considered SNPs with Pfixed if I
2 < 31%, or Prandom if I
2 >= 31%, 
within a factor of 100 of the peak SNP for comprehensive bioinformatic assessment. To 
ensure we were not missing potentially interesting functional candidates, HaploReg was 
used to identify additional SNPs within 200kb and with LD r2 >0.8 using 1000 Genomes pilot 
data36,75. GCTA was used to confirm that SNPs carried forward for bioinformatic assessment 
derived from a common signal. Following adjusting for the locus’ top SNP, the SNPs 
Law et al.,  
Page 20 of 32 
selected for bioinformatic annotation at 6p22.3, 7p21.1, 10q24, 11q13.3 and 15q13.1 had 
CMM association P > 0.01. At 9q31.2 a single SNP rs1484384 retained a modest melanoma 
association (P = 0.008) following adjusted for rs10739221; the rest were P > 0.01. At 2p22.2 
the SNPs with P-values within 2 orders of magnitude of the peak SNP rs6750047 included 
rs1800440, a non-synonymous SNP with limited LD with rs6750047 (LD r2 = 0.04). Following 
adjusting for rs6750047, rs1800440’s P was essentially unchanged (P = 4.3 × 10-4) and a 
second SNP rs163092 remained weakly associated with melanoma (P = 0.008); all other 
SNPs were P > 0.01. Adjustment for both rs6750047 and rs1800440 removed rs163092’s 
CMM association (P > 0.01). 
 
HaploReg36 and RegulomeDB39 were crosschecked to explore data reflecting transcription 
factor binding, open chromatin and the presence of putative enhancers. These tools 
summarize and collate data from public databases ENCODE 37, the Roadmap epigenomics 
project38 as well as a range of other functional tools . ENCODE and Roadmap have assayed 
a large number of different cell types including keratinocyte and melanocyte primary cells, 
and for a limited number of assay melanoma cell lines; predicted functional activity in these 
cell types was given priority over cell types less likely to be involved in the CMM risk. The 
summary results reported by HaploReg and RegulomeDB assign regions a putative function 
based on the combined results of multiple functional experiments and its position relative to 
known genes37,38. For example, ENCODE assigns the label of predicted enhancer to areas 
of open chromatin that overlaps a H3K4me1 signal, and binds transcription factors37. The 
Roadmap Epigenome uses as similar ranking system to ENCODE, and is summarized in the 
documentation for HaploReg36. For example, a weak enhancer will have only a weak 
H3K36me3 signal, while an active enhancer will have strong H3K36me3, H3K3me1 and 
H3K27ac signals. These labels are further divided into weak and strong depending on the 
quality of evidence. While these labels are predicted or putative, ENCODE reports that 
>50% of predicted enhancers are confirmed by follow up assays37, and these serve as a 
useful guide for interrogating CMM associated SNPs. Results from these tools were followed 
up in more detail using the UCSC genome browser58 to explore the ENCODE 37 and the 
Roadmap epigenomics project38 data. 
 
In addition, HaploReg uses genome-wide SNPs to estimate the background frequency of 
SNPs occurring in putative enhancer regions; this was used to test for enrichment in CMM 
associated SNPs with an uncorrected binomial test threshold of P = 0.0536. 
 
The eQTL browser (http://eqtl.uchicago.edu/Home.html), the Genotype-Tissue Expression 
dataset (GTEx)54, and the Multiple Tissue Human Expression Resource (MuTHER42,87) were 
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further interrogated to attempt to resolve potential genes influenced by disease associated 
SNPs. For these databases we report only cis results; details of cell types and definition of 
cis boundaries can be found in Supplementary Table S7. The peak SNP for each locus, as 
well as other functionally interesting SNPs identified by HaploReg and RegulomeDB were 
used to search listed eQTL databases. As the SNP coverage can differ for each database 
where SNPs of interest were not present in the eQTL datasets we searched using high LD 
(>0.95) proxies. While priority was given to cell types more likely to be involved in CMM 
biology (e.g. sun-exposed skin from GTEx or skin from MuTHER) we reported eQTLs from 
other tissue types to highlight any potential functional impact for identified SNPs. 
 
Regional plots of -log10P-values were generated using LocusZoom
88. Pair-wise LD between 
SNPs of interest was calculated in 379 European ancestry samples from 1000 genomes75 
using PLINK80. 
 
To test for any overlap with published GWAS association, results reported in the NHGRI 
catalog (http://www.genome.gov/gwastudies/) for reported loci were extracted on 24/07/2014 
and cross checked against the Stage one meta-analysis results. 
 
Additional methods 
 
Manhattan plots were generated in R based on scripts written by Stephen Turner 
(http://gettinggeneticsdone.blogspot.com.au/2011/04/annotated-manhattan-plots-and-qq-
plots.html). Forest plots were generated using the R rmeta package89. 
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Tables 
 
 
 
  
Stage one 
meta-
analysis 
Stage two 
meta-analysis 
Overall 
meta-
analysis 
SNP Region Gene 
Minor 
Allele:MAF 
(min INFO) 
Beta (P) Beta (P) Beta (P) 
rs6750047 2p22.2 
RMDN2 
(CYP1B1) 
A:0.43 
(0.96) 
0.088 
(2.9 × 10-7) 
0.113 
(6.0 × 10-3) 
0.092 
(7.0 × 10-9) 
rs6914598 6p22.3 CDKAL1 
C:0.32 
(0.88) 
0.11 
(2.6 × 10-8) 
0.037 
(0.63) 
0.10 
(3.5 × 10-8)* 
rs1636744 7p21.1 AGR3 
T:0.40 
(0.96) 
0.11 
(1.8 × 10-9) 
0.032 
(0.38) 
0.091 
(7.1 × 10-9) 
rs10739221 9q31.2 
TMEM38B 
(RAD23B, 
TAL2) 
T:0.24 
(0.94) 
0.12 
(9.6 × 10-9) 
0.145 
(1.7 × 10-3) 
0.12 
(7.1 × 10-11) 
rs2995264 10q24.33 OBFC1 
G:0.088 
(0.94) 
0.14 
(8.5 × 10-7) 
0.206 
(0.088) 
0.16 
(2.2 × 10-9) 
rs498136 11q13.3 CCND1 
A:0.32 
(0.97) 
0.12 
(1.0 × 10-10) 
0.124 
(4.0 × 10-3) 
0.12 
(1.5 × 10-12) 
rs4778138 15q13.1 OCA2 G:0.16 0.82 
-0.18 
(3.1 × 10-9) 
-0.156 
(1.7 × 10-3) 
-0.17 
(2.2 × 10-11) 
 
Table 1: Genome-wide significant results from a two-stage meta-analysis of GWAS of CMM from Europe, the USA and Australia. 
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For each region we report the chromosomal location, nearest gene, and any promising candidate in brackets for the top SNP. We also report 
the 1000 Genomes European population minor allele frequency (MAF) and minimum imputation quality across all studies (min INFO). The 
Stage one meta-analysis field reports the effect size estimate (beta) and P-value for the minor allele from the meta-analysis of 11 CMM GWAS, 
totaling 12,874 cases and 23,203 controls. Following their genotyping in three additional datasets (total 3,116 cases and 3,206 controls) we 
provide the Stage two meta-analysis results. Finally we provide the Overall meta-analysis of all available data. The results for the top SNP in 
each region that reached P < 1 × 10-6 in the Stage one and carried through to Stage two, per study results and evidence of heterogeneity of 
effect estimates across studies (I2) can be found in Supplementary Table S3. Where I2 values were below 31% fixed effects meta-analysis was 
used, otherwise random effects, and all genome-wide significant SNPs had Stage one and Overall I2 < 31%. Regions previously confirmed as 
associated with melanoma (e.g. MC1R) are not shown. We were unable to genotype rs186133190 in 2p15 and rs4731742 in 7q32.3 in the 
Stage two populations (see Online Methods). *Not genome-wide significant given a formal multiple testing correction e.g. P < 3.06 × 10-8 Li et 
al, (2012)90. 
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Figures 
 
 
Figure 1: Manhattan plot of the Stage one meta-analysis of GWAS of CMM from 
Europe, the USA and Australia. 
 
The Pfixed Stage one value for all SNPs present in at least two studies have been plotted 
using a log10(-log10) transform to truncate the strong signals at MC1R (P < 10
-92) on 
chromosome 16 and CDKN2A (P < 10-31) on chromosome 9. P < 5 × 10-8 (genome-wide 
significance) and P < 1 × 10-6 are indicated by a light and a dark line respectively, and 18 
loci reached genome-wide significance. The 2 newly-confirmed loci 11q13.3 (CCND1) and 
15q13.1 (HERC2/OCA2) are indicated by * and the 5 novel loci 2p22.2, 6p22.3, 7p21.1, 
9q31.2 and 10q24.33 are highlighted by a **. 2p22.2 (RMDN2/CYP1B1) and 10q24.33 
(OBFC1) were genome-wide significant only in the Overall meta-analysis (Supplementary 
Table S3). 
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Figure 2: Regional association plots for novel genome-wide significant loci 2p22.2, 
6p22.3, 7p21.1, 9q31.2, 10q24.33 and the newly-confirmed region, 15q13.1 (OCA2). 
 
Stage one negative log10(Pfixed) values for SNPs have been plotted against their genomic 
position (Mb) using LocusZoom88. The P-value and rs ID are listed for the peak SNP in each 
region (purple diamond). For the remaining SNPs the color indicates r2 with the peak SNP. 
Note FAM82A1’s alternative gene ID is RMND2. Neither rs2995264 in 10q24.33 nor 
rs6750047 in 2p22.2 are genome-wide significant in Stage one, but are in the Overall meta-
analysis. The plot for 11q13.3 (CCND1) can be found in Supplementary Figure S4. 
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